Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis 2023-10-16 07:48
Everest Medicines Announces Interim Results for First Half of 2023 2023-08-24 08:15
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential 2022-03-30 08:00
Phoenix Venture Partners LLC Raises 3rd Fund, PVP III LP 2021-02-01 20:06
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma 2021-01-25 15:00
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma 2020-12-11 21:00
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery 2020-12-07 22:37
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine 2020-09-18 15:00
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma 2020-07-01 07:30
Merck and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma 2020-04-09 18:00
Merck and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study 2020-03-13 20:00
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma 2020-01-06 20:00
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050 2019-11-28 00:34
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050 2019-11-25 08:15
Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial 2019-11-08 21:00
FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma 2019-05-15 08:25
ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-Infected With Tuberculosis 2018-03-06 01:00
Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer 2017-11-28 21:25
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma 2017-09-21 15:28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE 2017-08-11 08:18
1 2